QURE (QURE) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving QURE (QURE) right now is AMT-130 accelerated-approval path: The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. Revenue (Q1 2026) is ~$3.6M (mostly license and royalty). If that keeps playing out, the setup is favourable; the risk to it is uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. No one can predict where QURE trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive QURE (QURE) higher?
1. AMT-130 accelerated-approval path.
The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. AMT-130 carries RMAT, Breakthrough Therapy, and Fast Track designations, and Huntington's has no approved disease-modifying treatment, so a first-to-market gene therapy would define the company's value.
2. First-mover position in Huntington's.
Competing programs from Roche/Ionis, Wave, PTC, and others are either earlier stage or have stumbled, most notably Roche's tominersen, which failed to show meaningful clinical benefit. That leaves uniQure ahead of the field with the most advanced disease-modifying candidate and strong three-year efficacy data, at least for now.
3. Pipeline and platform optionality.
Beyond Huntington's, uniQure has early clinical programs in SOD1 ALS (AMT-162), refractory temporal-lobe epilepsy (AMT-260), and Fabry disease (AMT-191), plus royalties from the already-approved hemophilia B gene therapy Hemgenix, commercialized by CSL Behring. These provide additional shots on goal and some validation of the AAV platform.
4. Funded through key catalysts.
uniQure held roughly $587 million in cash, equivalents, and investments as of the first quarter of 2026, which management projects funds operations into the second half of 2029. That runway covers the planned BLA submission and a potential approval decision without an immediate need to raise capital under pressure.
What could weigh on QURE?
uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure burns tens of millions per quarter and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance.
Where QURE trades today
A forecast starts from where the stock actually is. These are QURE's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for QURE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a QURE forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the QURE guide and whether QURE is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the QURE outlook
The bottom line: what is driving QURE (QURE) is AMT-130 accelerated-approval path, with revenue (q1 2026) at ~$3.6M (mostly license and royalty). If that keeps playing out the setup is favourable; the risk is uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. No one can predict the price, so treat any QURE forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on QURE
- QURE stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is QURE a buy? (the case for, the risks, and a framework to decide)
- Does QURE pay a dividend?
Build a basket around QURE with Walnut
Use QURE as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for QURE (QURE)?
+
No one can reliably predict where QURE will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push QURE higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive QURE higher?
+
The main growth drivers are AMT-130 accelerated-approval path; First-mover position in Huntington's; Pipeline and platform optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to QURE?
+
uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure burns tens of millions per quarter and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance.
Will QURE stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. QURE's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is QURE a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the QURE "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.